Achilles Therapeutics’ £52.7 Million Series C Funding Round

Goodwin Procter LLP advised Achilles Therapeutics on the deal.

Achilles Therapeutics announced the completion of a £52.7 million oversubscribed Series C funding round. OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based, healthcare-focused institutional investors joined existing investors including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors, and Redmile Group.

Proceeds from this financing will be used to accelerate the company’s R&D activities and further build the clinical network to support the company’s ongoing Phase I/IIa trials, the THETIS trial in patients with recurrent or metastatic malignant melanoma and the CHIRON trial in patients with advanced non-small cell lung cancer. In addition, the financing will enable the continued build out of Achilles’ manufacturing capabilities and broaden its growing pipeline of solid tumour pre-clinical product candidates.

Achilles Therapeutics is a clinical stage, biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles was founded in 2016 by lead investor Syncona Ltd and is supported by an international syndicate of life science investors including RA Capital, Forbion, Invus, Perceptive Advisors, Redmile Group, OrbiMed, and Boxer Capital of Tavistock Group.

The Goodwin team was led by Sophie McGrath (Picture), Kenny Walker-Durrant, Matthew Lee, Jack Christian, Seo Salimi, Thomas Schaad, and Marishka DeToy.

Involved fees earner: Marishka DeToy – Goodwin Procter; Matthew Lee – Goodwin Procter; Sophie McGrath – Goodwin Procter; Seo Salimi – Goodwin Procter; Tom Schaad – Goodwin Procter; Kenny Walker-Durrant – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Achilles Therapeutics Ltd;

Print Friendly, PDF & Email